82.32
+3.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zoetis
From its filings with the US Securities and Exchange Commission
Zoetis is based in Parsippany, New Jersey. Its shares trade on NYSE under the ticker ZTS. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $9.47bn and net income of $2.67bn. At that date it held total assets of $15.47bn and shareholders' equity of $3.33bn.
Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. We have a diversified business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
Within each of these operating segments, we offer a diversified product portfolio for both companion animal and livestock customers so that we can capitalize on local trends and customer needs.
In addition, our Client Supply Services (CSS) organization, which provides contract manufacturing services to third parties, and our human health products, together represented approximately 1% of our total revenue for the year ended December 31, 2025.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Feb 2013
- Employees
- 14,500
- Website
- zoetis.com ↗
- Head office
- 10 SYLVAN WAY, PARSIPPANY, NJ, 07054
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael MccallisterNon-Executive Independent Chairman of the Board$490,000
- Ms. Kristin PeckChief Executive Officer, Director, since 2012$17.2m
- Mr. Wetteny JosephChief Financial Officer, Executive Vice President$5.1m
- Dr. Julie FullerChief Human Resources Officer, Executive Vice President and Global Operations
- Mr. Keith SarbaughExecutive Vice President, Chief Digital and Technology Officer
- Ms. Roxanne LaganoExecutive Vice President, General Counsel, Corporate Secretary$2.6m
- Mr. Nicholas AshtonExecutive Vice President, President - Global Manufacturing and Supply
- Ms. Jeannette AstorgaExecutive Vice President - Corporate Affairs, Communications, Chief Sustainability Officer
- Mr. Jamie BrannanExecutive Vice President, Chief Commercial Officer$3.0m
- Ms. Rimma DriscollExecutive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
- Mr. Kevin EschExecutive Vice President, President - Research & Development
- Ms. Stephanie TileniusDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 97
- Social
- 99
- Governance
- 66
- Direct emissions (scope 1)
- 111,637 t
- Energy emissions (scope 2)
- 177,750 t
- Value chain emissions (scope 3)
- 72,668 t
- Women in the workforce
- 48%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zoetis Inc is a leading global animal health company, enjoying a strong market presence and brand reputation.
- The company boasts a diverse portfolio of animal health products, including vaccines, diagnostics, and medicines.
- Zoetis Inc has a highly skilled and experienced workforce, enabling efficient research and development processes.
Weaknesses
- Zoetis Inc heavily relies on a few major customers, which poses a potential risk to its revenue if any customer reduces or discontinues their purchases.
- The company faces high regulatory requirements and strict compliance standards in the animal health industry, which may increase operational costs.
- Zoetis Inc has limited geographic diversification, with a significant portion of its revenue coming from sales in North America.
Opportunities
- The growing global concern for animal welfare and the increasing demand for quality healthcare products provide an opportunity for Zoetis Inc to expand its product offerings.
- The rise in pet ownership and the growing pet healthcare market offer potential for the company's growth.
- The advancement of technology, such as digital platforms and data analytics, can enable Zoetis Inc to enhance its research capabilities and develop innovative solutions.
Threats
- Zoetis Inc faces intense competition from both multinational corporations and local players in the animal health industry.
- Changes in government regulations and policies can impact market access, pricing, and product approvals.
- Economic downturns and fluctuations in currency exchange rates can affect the purchasing power and demand for animal health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.